BDR Pharmaceuticals launch Cabozantinib to treat thyroid cancer
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Subscribe To Our Newsletter & Stay Updated